- Previous Close
238.75 - Open
237.20 - Bid 231.00 x 1800
- Ask 251.47 x 900
- Day's Range
234.89 - 239.88 - 52 Week Range
132.24 - 255.18 - Volume
874,938 - Avg. Volume
1,007,631 - Market Cap (intraday)
35.096B - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
34.47 - EPS (TTM)
6.93 - Earnings Date Oct 24, 2024 - Oct 28, 2024
- Forward Dividend & Yield 2.12 (0.89%)
- Ex-Dividend Date Aug 15, 2024
- 1y Target Est
237.93
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
www.resmed.comRecent News: RMD
View MorePerformance Overview: RMD
Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RMD
View MoreValuation Measures
Market Cap
35.10B
Enterprise Value
35.73B
Trailing P/E
34.52
Forward P/E
26.81
PEG Ratio (5yr expected)
2.00
Price/Sales (ttm)
7.52
Price/Book (mrq)
7.22
Enterprise Value/Revenue
7.63
Enterprise Value/EBITDA
23.40
Financial Highlights
Profitability and Income Statement
Profit Margin
21.79%
Return on Assets (ttm)
12.70%
Return on Equity (ttm)
22.70%
Revenue (ttm)
4.69B
Net Income Avi to Common (ttm)
1.02B
Diluted EPS (ttm)
6.93
Balance Sheet and Cash Flow
Total Cash (mrq)
238.36M
Total Debt/Equity (mrq)
17.97%
Levered Free Cash Flow (ttm)
1.18B
Research Analysis: RMD
View MoreCompany Insights: RMD
RMD does not have Company Insights
Research Reports: RMD
View MoreLowering target price to $251.00
RESMED INC has an Investment Rating of HOLD; a target price of $251.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $263.00
RESMED INC has an Investment Rating of HOLD; a target price of $263.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $266.00
RESMED INC has an Investment Rating of HOLD; a target price of $266.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetResMed Earnings: Solid Result With Strong Mask Sales and Gross Margin Expansion
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
RatingPrice Target